The sequence of docetaxel‐cabazitaxel‐enzalutamid in men with metastatic castration‐resistant prostate cancer
02/2018
MUDr. Ivo Kocák, Ph.D.1, MUDr. Zdenek Řehák, Ph.D.2
1) Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
2) Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno
SUMMARY
In the present case, we present a possible sequential treatment for metastatic castration-resistant prostate cancer into the skeleton (mCRPC). Because of symptomatic disease, chemotherapy therapy has been launched that has been able to effectively reduce the symptoms of the disease. The tolerance of the docetaxel-cabazitaxel sequence was very good. Once the chemotherapy options have been exhausted, ARTA treatment with enzalutamide has been chosen, which further effectively stabilizes the disease, maintains overall good status. Sequential treatment of mCRPC has lasted nearly 4 years.
KEY WORDS
metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, enzalutamid
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...